Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 50

  • 1 641 clinical trials
  • 555 recruiting
  • 290 conditions
  • 28 countries

Conditions in this area

290 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma88Dermatitis atopic88HIV infection75Rheumatoid arthritis75Systemic lupus erythematosus61Multiple sclerosis59Psoriasis53Psoriatic arthropathy46Myasthenia gravis43Systemic scleroderma39Type 1 diabetes mellitus38Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Cardiac amyloidosis29Sjogren's syndrome29Interstitial lung disease28Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy23Vitiligo23Hereditary angioedema22Axial spondyloarthritis21+266

Clinical trials in Immune system disorders

1 641 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 641 clinical trials

Mite allergy

Not yet recruiting

Efficacy and safety of house dust mite allergoid (Dermatophagoides farinae, D. pteronyssinus, aluminium hydroxide) in people with moderate to severe house dust mite allergy

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Aluminium Hydroxide

Idiopathic pulmonary fibrosis

Not yet recruiting

Safety and Tolerability of Metformin in Patients with Idiopathic Pulmonary Fibrosis: A Randomized Placebo‑Controlled Phase II Study

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Philipps-Universitaet Marburg

Conjunctivitis allergic+2

Not yet recruiting

Efficacy and safety of allergenic extract of Olea europaea pollen polymerized with glutaraldehyde in patients with olive pollen allergy, including mild‑to‑moderate asthma

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Allergenic Extract Of Olea Europaea Pollen Polymerized With Glutaraldehyde
  • Sponsor:Inmunotek S.L.

Myasthenia gravis

Not yet recruiting

Efficacy and Safety of DNTH103 in Adults with Generalized Myasthenia Gravis: A Phase 3 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Dnth103
  • Sponsor:Dianthus Therapeutics Inc.

Systemic lupus erythematosus

Not yet recruiting

Study of dapirolizumab pegol placental transfer to infants in pregnant women with active systemic lupus erythematosus (drug combination)

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Benzocaine
  • Sponsor:UCB Biopharma

Colitis ulcerative

Not yet recruiting

Phase 2b Study of ATH-063 in Adults with Biologic‑Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years

Crohn's disease

Not yet recruiting

Efficacy and safety of ontunisertib in patients with fibrostenosing Crohn’s disease: a phase 2b randomized, double‑blind, placebo‑controlled dose‑ranging trial

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:ORG-129
  • Sponsor:Agomab Spain S.L.U.

Systemic lupus erythematosus

Not yet recruiting

Study of subcutaneous anifrolumab pharmacokinetics, pharmacodynamics and safety in children aged 5 to <18 years with systemic lupus erythematosus

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Allogenic stem cell transplantation+1

Not yet recruiting

Levofloxacin prophylaxis to reduce bloodstream infections in patients with hematologic malignancies undergoing allogeneic hematopoietic stem cell transplantation

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years
  • Substances:Levofloxacin
  • Sponsor:HUS-Yhtymae

Idiopathic pulmonary fibrosis

Not yet recruiting

Randomized Phase 3 Study of Deupirfenidone (LYT‑100) versus Pirfenidone in Adults with Idiopathic Pulmonary Fibrosis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Deupirfenidone
  • Sponsor:Puretech Lyt 100 Inc.

Dermatitis atopic

Not yet recruiting

Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Adults with Moderate to Severe Atopic Dermatitis (Phase 2 Study)

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years

Autoimmune hepatitis

Not yet recruiting

A Phase 2/3 Randomized Double‑Blind Study of Inebilizumab for Safety and Tolerability in Patients with Autoimmune Hepatitis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Inebilizumab
  • Sponsor:Amgen Inc.

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine39 clinical trialsTocilizumab38 clinical trialsTenofovir Alafenamide37 clinical trialsMethotrexate36 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.